Keros Therapeutics Inc. Stock News

Lexington, Mass. – December 13, 2021 – Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) is re-issuing this press release solely to correct inadvertent typographical errors under the heading "A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes," which incorrectly stated that none of the most commonly reported treatment-emergent adverse events observed as of the October 25, 2021 data cut-off date in the Phase 2 clinical trial of KER-050 were deemed to be related to study drug. However, one incidence each of nausea and diarrhea were attributed as related to study drug. All other data and disclosure remain unchanged.

LEXINGTON, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS), as well as preclinical data on the differentiated mechanism of action of KER-050 and its activity in cytopenia models, at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, held in person and virtually December 11 through 14, 2021. In addition, Keros announced preclinical data evaluating ALK2 inhibition as a potential treatment option for anemia of inflammation.

Keros Therapeutics, Inc. (NASDAQ:KROS) Stock analysts at Piper Sandler cut their Q4 2021 earnings per share estimates for Keros Therapeutics in a research report issued to clients and investors on Tuesday, December 7th. Piper Sandler analyst J. Catanzaro now anticipates that the company will earn ($0.87) per share for the quarter, down from their []

Keros Therapeutics, Inc. (NASDAQ:KROS) Research analysts at Piper Sandler decreased their Q4 2021 earnings estimates for shares of Keros Therapeutics in a research note issued on Tuesday, December 7th. Piper Sandler analyst J. Catanzaro now forecasts that the company will post earnings per share of ($0.87) for the quarter, down from their prior forecast []

Keros Therapeutics, Inc. (NASDAQ:KROS)s stock price gapped down prior to trading on Monday . The stock had previously closed at $54.16, but opened at $51.32. Keros Therapeutics shares last traded at $53.84, with a volume of 5,370 shares traded. KROS has been the topic of a number of analyst reports. HC Wainwright reaffirmed a buy []

Zacks Investment Research upgraded shares of Keros Therapeutics (NASDAQ:KROS) from a sell rating to a hold rating in a report released on Tuesday, Zacks.com reports. According to Zacks, Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The companys []

Zacks Investment Research upgraded shares of Keros Therapeutics (NASDAQ:KROS) from a sell rating to a hold rating in a research report sent to investors on Tuesday, Zacks.com reports. According to Zacks, Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal []

Related Stocks: CLDX , OCUL , NVRO , CTMX , CERS , IMTX , KROS , XFOR , AFMD , BCYC , ARCT , BBIO , CHAQ , PALI , EPIX , ECOR , SIEN , BCTX ,

LEXINGTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that it presented results from a preclinical study of a research form of KER-012 (RKER-012) at the American Heart Association (AHA) 2021 Scientific Sessions held November 13 through 15, 2021.

LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci

LEXINGTON, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci

LEXINGTON, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci

LEXINGTON, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci

LEXINGTON, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, de